Spots Global Cancer Trial Database for mf
Every month we try and update this database with for mf cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors | NCT02440685 | Lymphoma, Large... Lymphoma, Mantl... Lymphoma, Folli... Cancer Neoplasm Tumor Lymphoma, Malig... Lymphoma, B-cel... Lymphoma, Non-H... B-Cell Chronic ... B-Cell Leukemia... B-Lymphocytic L... Chronic Lymphoc... Leukemia, Lymph... Leukemia, Lymph... Myelofibrosis Chronic Idiopat... Idiopathic Myel... Lymphoma, T Cel... Peripheral T-Ce... T-Cell Lymphoma... | ASN002 Dose Esc... ASN002 RD | 18 Years - | Asana BioSciences | |
| Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With Myelofibrosis | NCT04454658 | Myelofibrosis (... | ABBV-744 Navitoclax Ruxolitinib | 18 Years - | AbbVie | |
| To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy (LIMBER-213) | NCT04629508 | Myelofibrosis Polycythemia Ve... Thrombocythemia | itacitinib | 18 Years - | Incyte Corporation | |
| Safety and Effectiveness of A-dmDT390-bisFv(UCHT1) Fusion Protein in Subjects With Mycosis Fungoides | NCT02943642 | Mycosis Fungoid... | A-dmDT390-bisFv... Vorinostat | 18 Years - | Angimmune LLC | |
| An Open-label Phase II Study of Lorvotuzumab Mertansine | NCT02420873 | Leukemia | Lorvotuzumab Me... | 18 Years - | M.D. Anderson Cancer Center | |
| A Study of MT-101 in Subjects With CD5+ Relapsed/Refractory TCL | NCT05138458 | Lymphoma, T-Cel... Lymphoma, T-Cel... Mycosis Fungoid... Adoptive Cellul... Cell Therapy | MT-101 MT-101 + Condit... | 18 Years - | Myeloid Therapeutics | |
| Panobinostat and Ruxolitinib in Primary Myelofibrosis, Post-polycythemia Vera-myelofibrosis or Post-essential Thrombocythemia-myelofibrosis | NCT01433445 | Idiopathic Myel... Post Essential ... Post Polycythem... | panobinostat ruxolitinib | 18 Years - | Novartis | |
| Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma | NCT05079282 | Relapsed or Ref... | ONO-4685 | 18 Years - | Ono Pharmaceutical Co. Ltd | |
| Doxycycline for the Treatment of Cutaneous T-Cell Lymphoma | NCT02341209 | Cutaneous T-cel... Mycosis Fungoid... Sezary Syndrome | Doxycycline mon... | 18 Years - | Rochester General Hospital | |
| Mechlorethamine Induced Contact Dermatitis Avoidance Study | NCT03380026 | Cutaneous T-cel... Cutaneous T-cel... Mycosis Fungoid... Folliculotropic... Granulomatous S... Syringotropic M... Mycosis Fungoid... Transformed Myc... | Triamcinolone Valchlor 0.016 ... | 18 Years - | Rochester Skin Lymphoma Medical Group, PLLC | |
| Jaktinib and Azacitidine In Treating Patients With MDS With MF or MDS/MPN With MF. | NCT04866056 | Myelodysplastic... Myeloproliferat... Myelofibrosis | Jaktinib azacitidine | 18 Years - | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | |
| Safety and Tolerability Study of Mivebresib Tablet Alone or in Combination With Ruxolitinib Tablet or Navitoclax Tablet in Adult Participants With Myelofibrosis | NCT04480086 | Myelofibrosis (... | Mivebresib Navitoclax Ruxolitinib | 18 Years - | AbbVie | |
| Tagraxofusp (SL-401) in Patients With CMML or MF | NCT02268253 | Myelofibrosis Chronic Myelomo... | SL-401 | 18 Years - | Stemline Therapeutics, Inc. | |
| Trial of Curcumin in Cutaneous T-cell Lymphoma Patients | NCT00969085 | Cutaneous T-cel... | Curcumin (Turme... Questionnaires Photos | - | M.D. Anderson Cancer Center | |
| Effectiveness of Imiquimod Topical Cream in Early Stage Cutaneous T-cell Lymphoma | NCT02301494 | Mycosis Fungoid... | 3.75% Imiquimod... 0.1% Fluocinoni... | 18 Years - | Rochester General Hospital | |
| To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313) | NCT04551066 | Myelofibrosis Primary Myelofi... Post Essential ... Post Polycythem... | parsaclisib ruxolitinib placebo | 18 Years - | Incyte Corporation | |
| CINC424A2X01B Rollover Protocol | NCT02386800 | Primary Myelofi... Polycythemia Ve... Graft Versus Ho... Acute Myeloid L... Thalassemia | ruxolitinib panobinostat | 1 Month - | Novartis | |
| An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib | NCT03952039 | Primary Myelofi... Post-Polycythem... Myelofibrosis | FEDRATINIB Best Available ... | 18 Years - | Celgene | |
| FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides) | NCT02448381 | Cutaneous T-Cel... | SGX301 (synthet... Placebo | 18 Years - | Soligenix | |
| FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides) | NCT02448381 | Cutaneous T-Cel... | SGX301 (synthet... Placebo | 18 Years - | Soligenix | |
| SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP) | NCT01352520 | CD-30 Positive ... Lymphoma, Prima... Lymphomatoid Pa... Mycosis Fungoid... Skin Lymphoma Cutaneous Lymph... Lymphoma Hematologic Dis... | SGN-35 | 18 Years - | M.D. Anderson Cancer Center | |
| Asian Phase II Study of INC424 in Patients With Primary Myelofibrosis (MF), Post-PV MF or Post-ET MF | NCT01392443 | Primary Myelofi... Post-Polycythem... Post-Essential ... | Ruxolitinib | 18 Years - 65 Years | Novartis | |
| FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides) | NCT02448381 | Cutaneous T-Cel... | SGX301 (synthet... Placebo | 18 Years - | Soligenix | |
| Study Evaluating Two Dose Levels of Targretin Capsules in Participants With Refractory Cutaneous T-Cell Lymphoma (CTCL) | NCT01007448 | Refractory Cuta... | Bexarotene | 18 Years - | Bausch Health Americas, Inc. | |
| Safety and Tolerability Study of Mivebresib Tablet Alone or in Combination With Ruxolitinib Tablet or Navitoclax Tablet in Adult Participants With Myelofibrosis | NCT04480086 | Myelofibrosis (... | Mivebresib Navitoclax Ruxolitinib | 18 Years - | AbbVie | |
| Study of Select Combinations in Adults With Myelofibrosis | NCT04283526 | Primary Myelofi... Myelofibrosis PMF Post-Essential ... Post-Polycythem... | MBG453 NIS793 Spartalizumab Decitabine | 18 Years - | Novartis | |
| Extension Study in Subjects Who Relapsed After Complete Response on Study KW-0761-001 | NCT01226472 | Peripheral T-ce... Cutaneous T-cel... | KW-0761 | 18 Years - | Kyowa Kirin Co., Ltd. | |
| FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides) | NCT02448381 | Cutaneous T-Cel... | SGX301 (synthet... Placebo | 18 Years - | Soligenix | |
| To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304) | NCT04551053 | Myelofibrosis Primary Myelofi... Post Essential ... Post Polycythem... | parsaclisib ruxolitinib placebo | 18 Years - | Incyte Corporation | |
| A Study of MT-101 in Subjects With CD5+ Relapsed/Refractory TCL | NCT05138458 | Lymphoma, T-Cel... Lymphoma, T-Cel... Mycosis Fungoid... Adoptive Cellul... Cell Therapy | MT-101 MT-101 + Condit... | 18 Years - | Myeloid Therapeutics | |
| An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib | NCT03952039 | Primary Myelofi... Post-Polycythem... Myelofibrosis | FEDRATINIB Best Available ... | 18 Years - | Celgene | |
| An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib | NCT03952039 | Primary Myelofi... Post-Polycythem... Myelofibrosis | FEDRATINIB Best Available ... | 18 Years - | Celgene | |
| A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors | NCT04686682 | NSCLC SCLC CRPC ESCC Ovarian Carcino... AML MF Malignant Tumor | JAB-8263 JAB-8263 | 18 Years - | Jacobio Pharmaceuticals Co., Ltd. | |
| Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm | NCT05025488 | Myelofibrosis Essential Throm... MPN | Peptide-based v... Poly ICLC | 18 Years - | Icahn School of Medicine at Mount Sinai |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
